NEW YORK, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Savara Inc. ("Savara Inc." or the "Company") (NASDAQ: SVRA) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Savara Inc. investors who were adversely affected by alleged securities fraud between March 4, 2024 and May 23, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/savara-inc-lawsuit-submission ...

Core Viewpoint - Investors in Savara Inc. have the opportunity to lead a securities fraud class action lawsuit due to alleged undisclosed information regarding the company's regulatory submissions and business prospects [1][2]. Summary by Relevant Sections Lawsuit Details - The lawsuit alleges that between March 7, 2024, and May 23, 2025, Savara failed to disclose critical information about the MOLBREEVI Biologics License Application (BLA), including insufficient details on its chemistry, manufacturing, and controls [2]. - It is claimed that the FDA was unlikely to approve the MOLBREEVI BLA in its current form, which would delay Savara's submission timeline and increase the need for additional capital [2]. - The lawsuit asserts that the positive statements made by the defendants regarding the company's business and prospects were materially misleading and lacked a reasonable basis [2]. Participation Information - Investors who suffered losses on their Savara investments are encouraged to participate in the lawsuit before the lead plaintiff deadline of November 7, 2025 [2]. - Interested parties can contact Glancy Prongay & Murray LLP for more information or to learn about their rights regarding the lawsuit [3][4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Savara Inc. securities during the specified class period of the upcoming lead plaintiff deadline on November 7, 2025, for a class action lawsuit [1][2]. Group 1: Class Action Details - Investors who bought Savara securities between March 7, 2024, and May 23, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by the November 7, 2025 deadline [2]. Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting its own achievements, including the largest securities class action settlement against a Chinese company at the time [3]. - The firm has been consistently ranked among the top firms for securities class action settlements, recovering hundreds of millions of dollars for investors, including over $438 million in 2019 alone [3]. Group 3: Case Allegations - The lawsuit alleges that Savara's defendants made false or misleading statements regarding the MOLBREEVI Biologics License Application, which lacked sufficient information for FDA approval [4]. - It is claimed that the delay in regulatory approval increased the likelihood of Savara needing to raise additional capital, and that the public statements made by the defendants were materially false and misleading [4].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Savara Inc. regarding a class action lawsuit related to misleading statements about the company's drug application process for MOLBREEVI BLA [1][3]. Group 1: Allegations - The complaint alleges that during the class period from March 4, 2024, to May 23, 2025, Savara Inc. made materially false and misleading statements regarding the MOLBREEVI BLA treatment for pulmonary alveolar proteinosis [3]. - Specific allegations include a lack of sufficient information about MOLBREEVI's chemistry, manufacturing, and controls, which made FDA approval unlikely in its current form [3]. - The delay in regulatory approval raised concerns that Savara would need to raise additional capital, contradicting the company's public statements [3]. Group 2: Class Action Details - Shareholders who purchased shares of SVRA during the specified class period are encouraged to register for the class action, with a deadline of November 7, 2025, to seek lead plaintiff status [4]. - Once registered, shareholders will receive updates through a portfolio monitoring software regarding the case's progress [4]. - Participation in the case incurs no cost or obligation for the shareholders [4]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [5]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [5].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Savara Inc. regarding a class action lawsuit due to alleged misleading statements related to the approval of the MOLBREEVI BLA treatment for pulmonary alveolar proteinosis [1]. Summary by Sections Allegations - The complaint alleges that during the class period from March 4, 2024, to May 23, 2025, Savara Inc. made materially false and misleading statements regarding the MOLBREEVI BLA, including: - Lack of sufficient information about MOLBREEVI's chemistry, manufacturing, and controls [1]. - Unlikelihood of FDA approval for the MOLBREEVI BLA in its current form [1]. - Delay in submission of the MOLBREEVI BLA within the previously represented timeframe [1]. - Increased likelihood of needing to raise additional capital due to regulatory approval delays [1]. - Overall, the public statements made by the defendants were materially false and misleading throughout the relevant period [1]. Next Steps for Shareholders - Shareholders who purchased shares of Savara Inc. during the specified class period are encouraged to register for the class action by November 7, 2025, to potentially be appointed as lead plaintiffs [2]. - Registered shareholders will receive updates through a portfolio monitoring software regarding the status of the case [2]. Firm's Mission - The Gross Law Firm aims to protect the rights of investors affected by deceit, fraud, and illegal business practices, ensuring companies adhere to responsible business practices [3].

LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (the "Company†) (Nasdaq: SVRA), a clinical- stage biopharmaceutical company focused on rare respiratory diseases, today announced additional analyses from its pivotal Phase 3 IMPALA-2 clinical trial of molgramostim in aPAP were presented as poster presentations at the ERS Congress 2025 in Amsterdam, The Netherlands. ERS 2025 Posters Savara Title: Efficacy of Inhaled Molgramostim According to Severity of Autoimmune Pulmonary Alveolar Proteinosis (aPAP). ...

Core Viewpoint - Investors in Savara Inc. have the opportunity to lead a securities fraud class action lawsuit due to substantial losses incurred as a result of misleading statements made by the company regarding its regulatory submissions and business prospects [1][3]. Summary by Relevant Sections Lawsuit Details - The lawsuit alleges that from March 7, 2024, to May 23, 2025, Savara failed to disclose critical information about the MOLBREEVI Biologics License Application (BLA), including insufficient data on its chemistry, manufacturing, and controls [3]. - It is claimed that the FDA was unlikely to approve the MOLBREEVI BLA in its current form, which would delay the submission process beyond what was communicated to investors [3]. - The delay in regulatory approval raised the likelihood that Savara would need to seek additional capital, contradicting the positive statements made by the company regarding its business and operational prospects [3]. Investor Participation - Investors who suffered losses are encouraged to contact the Law Offices of Howard G. Smith before November 7, 2025, to participate in the ongoing class action lawsuit [2][4]. - Participation does not require immediate action; investors may choose to retain counsel or remain absent from the class action [5].

Accessibility StatementSkip Navigation NEW YORK, Sept. 26, 2025 /PRNewswire/ -- Levi &Â Korsinsky, LLP notifies investors in Savara Inc. ("Savara Inc." or the "Company") (NASDAQ: SVRA) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Savara Inc. investors who were adversely affected by alleged securities fraud between March 4, 2024 and May 23, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/ ...

Core Viewpoint - A class action lawsuit has been filed against Savara Inc. for alleged violations of securities laws, specifically related to misleading statements regarding its Biologics License Application (BLA) for MOLBREEVI [1][2]. Group 1: Lawsuit Details - The class period for the lawsuit is from March 7, 2024, to May 23, 2025, with a deadline for lead plaintiff appointments set for November 10, 2025 [2]. - The complaint alleges that Savara made false and misleading statements to the market, particularly regarding the adequacy of information provided in its BLA submitted to the FDA [2]. - It is claimed that the FDA was unlikely to approve Savara's BLA due to deficiencies in the information provided, which rendered the company's public statements materially misleading throughout the class period [2]. Group 2: Shareholder Participation - Shareholders who purchased shares during the specified class period are encouraged to contact the law firm for potential lead plaintiff appointments, although this is not a requirement for recovery [2][3]. - Once registered, shareholders will be enrolled in a portfolio monitoring system to receive updates on the case's status, with no cost or obligation to participate [3]. Group 3: Law Firm Background - DJS Law Group specializes in securities class actions and corporate governance litigation, focusing on enhancing investor returns through advocacy [4]. - The firm represents some of the largest hedge funds and alternative asset managers, emphasizing the value of litigation claims as significant assets [4].

LOS ANGELES, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP reminds investors of the upcoming November 7, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Savara Inc. (“Savara” or the “Company”) (NASDAQ: SVRA) securities between March 7, 2024 and May 23, 2025, inclusive (the “Class Period”). IF YOU SUFFERED A LOSS ON YOUR SAVARA INVESTMENTS, CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOU ...